Navigation Links
Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
Date:4/2/2008

AMSTERDAM, The Netherlands, April 2 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Dr. George Morstyn to be appointed to the Supervisory Board at its Annual General Meeting of shareholders on April 16, 2008. Dr. Morstyn (MB BS PhD FRACP), who retired as Senior Vice President of Development at Amgen, was a member of Amgen's executive committee and responsible for global preclinical and clinical development as well as regulatory affairs.

Dr. Morstyn also played an active role in representing Amgen to the financial community. Five new drugs and many label extensions were approved during his 11 year tenure. Dr. Morstyn graduated from Monash University, completed a Ph.D. with Professor Donald Metcalf at the Walter and Eliza Hall Institute and trained in medical oncology at the National Cancer Institute in the US. He was Head of the Clinical Program of the Ludwig Institute for Cancer Research in Melbourne for eight years. Dr. Morstyn was an early clinical investigator of several biological agents prior to joining Amgen, and performed seminal work on the development of G-CSF, which later became Neupogen, Amgen's second blockbuster drug. Dr. Morstyn is currently a board member of several Australian biotechnology companies.

Further to a plan of rotation, AMT aims to build a fully independent Supervisory Board in the course of 2008. Earlier this year, AMT announced the nominations of Alexander Ribbink, COO of TomTom, and Philippe van Holle, Head of Celgene Europe, to its Supervisory Board.

AMT's AGM is scheduled for April 16, 10:30 a.m., and will take place at the Rosarium, Amsterdam, The Netherlands.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a ma
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
7. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
8. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
9. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
10. NIST team proves bridge from conventional to molecular electronics possible
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...NNA, Austria, November 6 EUCODIS B...facturing, and marketing enzymes for the,chemical ...a research,agreement with Bio Sidus, the leading b... The agreement gives EUCODIS Bioscience exclusi...- to Bio Sidus, proprietary collection of,psychrop...
(Date:11/6/2009)..., Calif., Nov. 6 Intarcia Therapeu...s ITCA 650 (DUROS® continuous delivery of exe...es at the Ninth Annual Diabetes Technology Meeting...wscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,...Via ITCA 650 Lowers Plasma Glucose, HbA1c and Redu...
(Date:11/5/2009)...TON, Colo., Nov. 5 The endangered ...the western U.S. This rare carnivore feeds on pra... to plague and often entire population die-offs in...e (FWS) has implemented a ferret breeding program ...to their formerly native habitat. Unfortunately, ...
(Date:11/5/2009)...nce Call on Thursday, November 5, 2009 at 4:30 p.m...v. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceut...: OGXI ) today reported unaudited financial resul...tember 30, 2009 and reviewed the Company,s highlig...wing consolidated results reflect the operations o...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...he,state stem cell agency by California,s Controll...t created the agency, Consumer Watchdog said today...iang found that with a,relatively minor exception ... (CIRM) complies with the requirements of Proposit... they relate to conflict-of-interest,policies, gra...
...of Financing for $3 Million, PITTSBURGH, May 12 ...athology, Inc.,s PathFinderTG(R) have fueled the,c...of-the-art headquarters,in Pittsburgh and the grow..., up from 20 a year ago. Against this backdrop, th...sider round of financing for $3 million. The,proce...
...Pink Sheets: MEDQ), the largest Medical Transcript...riday, May 9th, filed its Form 10-Q quarterly,repo...n for the quarter,ended March 31, 2008., Revenue ...with $89.1M,in the first quarter of 2007. The decr... period was primarily due to customer losses exper...
Other Biology Technology:Controller's Stem Cell Agency Audit Ignores California Agency's Built-in Flaws 2Controller's Stem Cell Agency Audit Ignores California Agency's Built-in Flaws 3Expansion and Relocation to New, State-Of-The-Art Facilities Marks Milestone in Effort to Roll Out New Tool for Cancer Diagnosis 2Expansion and Relocation to New, State-Of-The-Art Facilities Marks Milestone in Effort to Roll Out New Tool for Cancer Diagnosis 3MedQuist Reports First Quarter 2008 Results 2MedQuist Reports First Quarter 2008 Results 3MedQuist Reports First Quarter 2008 Results 4MedQuist Reports First Quarter 2008 Results 5MedQuist Reports First Quarter 2008 Results 6MedQuist Reports First Quarter 2008 Results 7MedQuist Reports First Quarter 2008 Results 8MedQuist Reports First Quarter 2008 Results 9
(Date:11/5/2009)... Conn.Researchers at Yale University have develope...y,s immune response to HIV and HIV-infected cells,...gs, published online in the Journal of the Americ...tic approaches for these diseases. , The molecu...g HIV" (ARM-H) and "antibody-recruiting molecule t...
(Date:11/4/2009)...(top news in natural science) , United States ... less water today than it did 35 years ago, despit...ter use are partly attributable to alternative coo...rigation systems. According to the latest USGS wat...e United States goes to cooling thermoelectric pow...
(Date:11/4/2009)... BC - Lowly bacteria, it turns out, hold the power...ants around the world clean up toxic waste on test...cally RDX, were invented back in World War II and ... These high-energy compounds are often used to pro...on of TNT. , But with increased knowledge of t...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Genomic research will enable greener cleanup of military explosive test sites 2China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 1China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 2China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 3VIDEO from Medialink and CIGNA 3A Dont Stress Out Over Stress Some of it is Good for You 58857 1VIDEO from Medialink and CIGNA 3A Dont Stress Out Over Stress Some of it is Good for You 58857 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 1Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 4
...nable part of the world,s energy future, especiall...ly abandoned or degraded agricultural lands, repor...nford University. Using these lands for energy cro...earing new land, avoids competition with food prod... to mitigate climate change. Sustainable bioenergy...
...ite near Pulborough, West Sussex, has thrown remar...ast Neanderthals. It provides a snapshot of a thri...es on the verge of extinction. , "The tools we,ve...d potentially older than tools in Britain belongin...ew Pope of Archaeology South East based at the UCL...
...Foundation for the Advancement of Military Medicin...he Health Sciences (USU) are holding the first-eve...researchers and clinicians to discuss current and ...WHAT: USU-HJF Symposium, Experts in their respecti...reaking work being undertaken within the DoD medic...
Other Biology News:Abandoned farmlands are key to sustainable bioenergy 2Britain's last Neanderthals were more sophisticated than we thought 2
GIBCO BGJb Medium (Fitton-Jackson Modification) (1X) liquid from Invitrogen
11(R)-HETE from Cayman Chemical
Rabbit Anti-T-box 6 Monoclonal Antibody, Unconjugated, Clone PADZMD.501 from Invitrogen
Rat Anti-karyopherin alpha2 Monoclonal Antibody, Unconjugated, Clone 2G7 from Santa Cruz Biotechnology, Inc.
Biology Products: